EUVIMEDEUVIMED entdecken
Crossref

Light Chain Q166C Mutation Permits One‐step Site Specific Conjugation on Monoclonal Antibodies

Mingying Li, Chunyu Song, Jiayun Li, Junting Min, Lei Cao, Lin Wang, Ningning Ma iD

ChemBioChem · 2023

DOI: 10.1002/cbic.202200780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2023. Verfasst von Mingying Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province, 110016, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immunoconjugates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Engineered cysteines are frequently used for site‐specific conjugation in antibody‐drug conjugate (ADC) development. When cysteine‐engineered mAbs are produced in the cell culture process, the sulfhydryl groups on the engineered cysteines are mostly in an oxidized form. The oxidized cysteines require multiple steps (such as reduction, reoxidation, and buffer exchanges) to reactivate for bioconjugation, which complicates the ADC production process and reduces yields. In this study, we identified a Q166C mutation in the light chain that allows the presence of free sulfhydryl groups during cell culture and purification process. This mutation is in the constant region and away from sites involved in antigen binding or Fc‐mediated functions. The free sulfhydryl reacts readily with maleimide in a mild solution at a high conjugation rate. This is only the second such site reported (the first one is Q124C in the light chain). Using the Q166C mutation, we conjugated an anti‐angiopoietin‐2 (Ang‐2) peptide on bevacizumab, an anti‐vascular endothelial growth factor (VEGF) antibody, to construct a peptide antibody conjugate, Ava‐Plus, which could block two pro‐angiogenic factors simultaneously. Ava‐Plus showed high affinity for both VEGF and Ang‐2 and demonstrated higher activity than bevacizumab in in vitro cell migration and in vivo mouse xenograft models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalImmunoconjugatesMiceHumansAnimalsVascular Endothelial Growth Factor ABevacizumabCysteineSulfhydryl Compounds

Stichwörter der Autor:innen

Ang-2VEGFangiogenesisfree sulfhydrylsite-specific conjugation

Substanzen

Antibodies, MonoclonalVascular Endothelial Growth Factor ABevacizumabCysteineSulfhydryl CompoundsImmunoconjugates

Autor:innen und Institutionen

  • Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province, 110016, China.
  • School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province, 110016, China.

ORCID-Profile: Ningning Ma

Zitieren

APA

Li, M., Song, C., Li, J., Min, J., Cao, L., Wang, L., & Ma, N. (2023). Light Chain Q166C Mutation Permits One‐step Site Specific Conjugation on Monoclonal Antibodies. ChemBioChem. https://doi.org/10.1002/cbic.202200780

Vancouver

Li M, Song C, Li J, Min J, Cao L, Wang L, et al. Light Chain Q166C Mutation Permits One‐step Site Specific Conjugation on Monoclonal Antibodies. ChemBioChem. 2023. doi:10.1002/cbic.202200780

BibTeX
@article{Li2023,
  author = {Li, Mingying and Song, Chunyu and Li, Jiayun and Min, Junting and Cao, Lei and Wang, Lin and Ma, Ningning},
  title = {Light Chain Q166C Mutation Permits One‐step Site Specific Conjugation on Monoclonal Antibodies},
  journal = {ChemBioChem},
  year = {2023},
  doi = {10.1002/cbic.202200780}
}
Kostenlos starten →